Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Other financing activities (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Other financing activities for 4 consecutive years, with $98000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities fell 70.21% to $98000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 46.69% year-over-year, with the annual reading at $1.2 million for FY2025, 46.69% up from the prior year.
  • Other financing activities hit $98000.0 in Q4 2025 for Axsome Therapeutics, down from $189000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $12.4 million in Q2 2023 to a low of -$14.2 million in Q4 2023.
  • Historically, Other financing activities has averaged $828583.3 across 4 years, with a median of $361000.0 in 2024.
  • Biggest five-year swings in Other financing activities: tumbled 98.19% in 2024 and later surged 129.78% in 2025.
  • Year by year, Other financing activities stood at $6.5 million in 2022, then plummeted by 319.27% to -$14.2 million in 2023, then skyrocketed by 102.31% to $329000.0 in 2024, then plummeted by 70.21% to $98000.0 in 2025.
  • Business Quant data shows Other financing activities for AXSM at $98000.0 in Q4 2025, $189000.0 in Q3 2025, and $517000.0 in Q2 2025.